0001415889-24-018081.txt : 20240624
0001415889-24-018081.hdr.sgml : 20240624
20240624202310
ACCESSION NUMBER: 0001415889-24-018081
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: KALA BIO, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 241065959
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
FORMER COMPANY:
FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20091223
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kharabi Darius
CENTRAL INDEX KEY: 0001893729
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O KALA PHARMACEUTICALS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
144
1
primary_doc.xml
144
0001893729
XXXXXXXX
LIVE
0001479419
KALA BIO, INC.
001-38150
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
781-996-5252
Darius Kharabi
Officer
Common Stock
ETRADE FINANCIAL CORPORATION
3 EDISON DRIVE
ALPHARETTA
GA
30005
4830
23662.05
2816454
06/24/2024
NASDAQ
Common Stock
06/24/2024
Restricted Stock Unit Vesting
Issuer
N
12281
06/24/2024
Equity Compensation
N
ETRADE FINANCIAL CORPORATION
3 EDISON DRIVE
ALPHARETTA
GA
30005
Common Stock
05/31/2024
231
1405.74
Represents the sale of shares of common stock pursuant to a "sell-to-cover" transaction in order to satisfy tax withholding obligations in connection with the vesting of RSUs previously granted to the Reporting Person. This sale was effected pursuant to an automatic sell-to-cover instruction effected pursuant to Rule 10b5-1 adopted by the Reporting Person on November 16, 2021 and does not represent a discretionary sale by the Reporting Person.
06/24/2024
/s/ Mary Reumuth, Attorney-in-Fact